Clinical Trials Browser

Prostatic Neoplasms × Imatinib Mesylate × Clear all

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT00038194 2018-10-31

Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer

Phase 1 Completed

28 enrolled

Genitourinary

Prostatic Neoplasms

NCT01316458 2017-06-01

Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy

Phase 2 Completed

51 enrolled

Genitourinary

Abdominal Neoplasms, Genital Diseases, Male, Genital Neoplasms, Male, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

NCT00861471 2016-06-30

Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer

Phase 1/2 Terminated

24 enrolled 11 charts

Genitourinary

Prostatic Neoplasms

NCT00500110 2015-04-28

Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer

Phase 2 Completed

39 enrolled 6 charts

Genitourinary

Prostatic Neoplasms

NCT00424385 2014-07-21

Study Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgen-independent Prostate Cancer (AIPC)

Phase 1 Completed

17 enrolled 8 charts

Genitourinary

Prostatic Neoplasms

NCT00084825 2012-10-26

Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008

Phase 2 Completed

23 enrolled

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT00080678 2012-10-12

Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases

Phase 2 Completed

116 enrolled

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Clinical Trials

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer

Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy

Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer

Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer

Study Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgen-independent Prostate Cancer (AIPC)

Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008

Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases